V3 loop of human immunodeficiency virus type 1 reduces cyclin E expression and induces G1 arrest in interleukin 2-dependent T cells

AIDS Research and Human Retroviruses

Volumn 14, Issue 1, 1998, Pages 31-38

  Sakaida, Hitoshi ^a   Kawamata, Shin ^a   Hattori, Toshio ^a   Uchiyama, Takashi ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN E; INTERLEUKIN 2; RETINOBLASTOMA PROTEIN;

ARTICLE; CELL CYCLE G1 PHASE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN T CELL LEUKEMIA VIRUS; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; T LYMPHOCYTE;

EID: 0031964777     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.1998.14.31     Document Type: Article

References (61)

1. Levy JA: Pathogenesis of human immunodeficiency virus infection. Microbiol Rev 1993;57:183-289.
2. Fauci A: Immunopathogenic mechanisms and research strategies. Clin Res 1988;35:503-510.
3. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, and Markowitz M: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature (London) 1995;373:123-126.
4. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, Lifson JD, Bonhoeffer S, Nowak MA, Hahn BH, Saag MS, and Shaw GM: Viral dynamics in human immunodeficiency virus type 1 infection. Nature (London) 1995;373:117-122.
5. Finkel TH, Tudor-Williams G, Banda NK, Cotton MF, Curiel T, Monks C, Baba TW, Ruprecht RM, and Kupfer A: Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV-1 and SIV-infected lymph nodes. Nature Med 1995;1:129-134.
6. Finkel TH and Banda NK: Indirect mechanisms of HIV pathogenesis: How does HIV kill T cells? Curr Opin Immunol 1994;6: 605-615.
7. Terai C, Kornbluth RS, Pauza CD, Richman DD, and Carson DA: Apoptosis as a mechanism of cell death in cultured T lymphoblasts acutely infected with HIV-1. J Clin Invest 1991;87:1710-1715.
8. Laurent CAG, Krust B, Muller S, Riviere Y, Rey-Cuille MA, Bechet JM, Montagnier L, and Hovanessian AG: The cytopathic effect of HIV is associated with apoptosis. Virology 1991;185: 829-839.
9. Ameisen JC and Capron A: Cell dysfunction and depletion in AIDS: The programmed cell death hypothesis. Immunol Today 1991;12:102-105.
10. Gougeon ML, Olivier R, Garcia S, Guetard D, Dragic T, Dauguet C, and Montagnier L: Demonstration of an engagement process towards cell death by apoptosis in lymphocytes of HIV infected patients. CR Acad Sci III 1991;312:529-537.
11. Meyaard L, Otto SA, Jonker RR, Mijnster MJ, Keet RP, and Miedema F: Programmed death of T cells in HIV-1 infection. Science 1992;257:217-219.
12. Banda NK, Bernier J, Kurahara DK, Kurrle R, Haigwood N, Sekaly RP, and Finkel TH: Crosslinking CD4 by human immunodeficiency virus gp120 primes T cells for activation-induced apoptosis. J Exp Med 1992;176:1099-1106.
13. Chirmule N, Kalyanaraman VS, Oyaizu N, Slade H, and Pahwa S: Inhibition of functional properties of tetanus antigen-specific T-cell clones by envelope glycoprotein gp120 of human immunodeficiency virus. Blood 1990;75:152-159.
14. Shalaby MR, Krowka JF, Gregory TJ, Hirabayashi SE, McCabe SM, Kaufman DS, Stites DP, and Ammann AJ: The effects of human immunodeficiency virus recombinant envelope glycoprotein on immune cell functions in vivo. Cell Immunol 1987;110: 140-148.
15. Mann DL, Lasone F, Popovic M, Arthur LO, Robey WG, Blattner WA, and Newman MJ: HTLV-III large envelope protein (gp120) suppresses PHA-induced lymphocyte blastogenesis. J Immunol 1987;138:2640-2644.
16. Krowka JF, Stiles D, Mills J, Hollander H, McHugh T, Busch M, Wilhelm L, and Blackwood L: Effect of interleukin 2 and large envelope glycoprotein (gp120) of human Immunodeficiency virus (HIV) on lymphocyte proliferative responses to cytomegalovirus. Clin Exp Immunol 1988;72:179-185.
17. Weinhold KJ, Lyerly HK, Stanley SD, Austin AA, Matthews TJ, and Bolognesi DP: HIV-1 gp120-mediated immune suppression and lymphocyte destruction in the absence of viral infection. J Immunol 1989;142:3091-3097.
18. Oyaizu N, Chirmule N, Kalyanaraman VS, Hall WW, Good RA, and Pahwa S: Human immunodeficiency virus type 1 envelope glycoprotein gp120 produces immune defects in CD4+ T lymphocytes by inhibiting interleukin 2 mRNA. Proc Natl Acad Sci USA 1990;87:2379-2383.
19. cdc2. J Virol 1995;69:6705-6711.
20. Rogel ME, Wu LI, and Emerman M: The immunodeficiency virus type 1 vpr gene prevents cell proliferation during chronic infection. J Virol 1995;69:882-888.
21. Sakaida H, Murakami T, Kawamata S, Hattori T, and Uchiyama T: V3 loop of human immunodeficiency virus type 1 suppresses IL-2-induced T cell growth. AIDS Res Hum Retroviruses 1997;13:151-159.
22. Bates S, Bonetta L, MacAllan D, Parry D, Holder A, Dickson C, and Peters G: CDK6(PLSTIRE) and CDK4(PSK-J3) are a distinct subset of the cyclin-dependent kinases that associate with cyclin D1. Oncogene 1994;9:71-79.
23. Dou QP, Levin AH, Zhao S, and Pardee AB: Cyclin E and cyclin A as candidates for the restriction point protein. Cancer Res 1993;53:1493-1497.
24. Koff A, Giordano A, Desai D, Yamashita K, Harper JW, Elledge S, Nishimoto T, Morgan DO, Franza BR, and Roberts JM: Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle. Science 1992;257:1689-1694.
25. Matsuoka M, Kato JY, Fisher RP, Morgan DO, and Sherr CJ: Activation of cyclin-dependent kinase 4(cdk4) by mouse MO15-associated kinase. Mol Cell Biol 1994;14:7265-7275.
26. PSK-J3/cdk4) for mammalian D type G1 cyclins. Cell 1992;71:323-334.
27. Matsushime H, Quelle DE, Shurtleff SA, Shibuya M, Sherr CJ, and Kato JY: D-type cyclin-dependent kinase activity in mammalian cells. Mol Cell Biol 1994;14:2066-2076.
28. Meyerson M and Harlow E: Identification of G1 kinase activity for cdk6, a novel cyclin D partner. Mol Cell Biol 1994;14:2077-2086.
29. Pagano M, Pepperkok R, Lucas J, Baldin V, Ansorge W, Bartek J, and Draetta G: Regulation of the cell cycle by the cdk2 protein kinase in cultured human fibroblasts. J Cell Biol 1993;121: 101-111.
30. Resnitsky D, Gossen M, Bujard H, and Reed SI: Acceleration of the G1/S phase transition by expressing of cyclin D1 and E with an inducible system. Mol Cell Biol 1994;14:1669-1679.
31. Tsai L, Lees E, Faha B, Harlow E, and Riabowol K: The cdk2 kinase is required for the G1 to S transition in mammalian cells. Oncogene 1993;8:1593-1602.
32. Xiong Y, Zhang H, and Beach D: D-type cyclins associate with multiple protein kinases and the DNA replication and repair factor PCNA. Cell 1992;71:505-514.
33. Norbury C and Nurse P: Animal cell cycle and their control. Ann Res Biochem 1992;61:441-470.
34. Hinds PW, Mittnacht S, Dulic V, Arnold A, Reed SI, and Weinberg RA: Regulation of retinoblastoma protein functions by ectopic expression of human cyclins. Cell 1992;70:993-1006.
35. Koff A, Cross F, Fisher A, Schumacher J, Leguellec K, Phillipe M, and Robert JM: Human cyclin E, a new cyclin that interacts with two members of the CDC2 gene family. Cell 1993;66:1217-1228.
36. Lew DJ, Dulic V, and Reed SI: Isolation of three novel human cyclins by rescue of G1 cyclin (Cln) function in yeast. Cell 1991;6:1197-1206.
37. Murakami T, Hattori T, and Takatuki K: A principal neutralizing domain of human immunodeficiency virus type 1 interacts with proteinase-like molecule(s) at the surface of Molt-4 clone 8 cells. Biochim Biophys Acta 1991;1079:279-284.
38. Ratner L, Haseltine W, Patarca R, Livac KJ, Starcich B, Josephs SF, Doran ER, Rafalski JA, Whitehorn EA, Baumeister K, Ivanoff L, Patteway SR Jr, Pearson ML, Lautenberger JA, Papas TS, Ghrayeb L, Chang NT, Gallo RC, and Wong-Staal F: Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature (London) 1985;313:277-284.
39. Matsushita S, Robert-Guroff M, Rusche J, Koito A, Hattori T, Hoshino H, Javaherian K, Takatuki K, and Putney S: Characterization of a human immunodeficiency virus neutralizing monoclonal antibody and mapping of the neutralizing epitope. J Virol 1988;62:2107-2114.
40. Wild C, Oas T, McDanal C, Bolognesi D, and Matthews T: A synthetic peptide inhibitor of human immunodeficiency virus replication: Correlation between solution structure and viral inhibition. Proc Natl Acad Sci USA 1992;89:10537-10541.
41. Wild CT, Shugars DC, Greenwell TK, McDanal CB, and Matthews TJ: Peptides corresponding to a predictive a-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci USA 1994;91:9770-9774.
42. Hori T, Uchiyama T, Tsudo M, Umadome H, Ohno H, Fukuhara S, Kita K, and Uchino H: Establishment of an interleukin 2-dependent human T cell line from a patient with T cell chronic lymphocytic leukemia who is not infected with human T cell leukemia/lymphoma virus. Blood 1987;70:1069-1072.
43. Qin XQ, Chittenden T, Livingston DM, and Kaelin WG: Identification of a growth suppression domain within the retinoblastoma gene product. Genes Dev 1992;6:953-964.
44. cdc2 kinase activity is associated with G1/S-phase growth arrest in T lymphocytes. J Biol Chem 1993;268:3734-3738.
45. Ewen ME, Sluss HK, Sherr CJ, Matsushime H, Kato JY, and Livingston DM: Functional interactions of the retinoblastoma protein with mammalian D-type cyclins. Cell 1993;73:487-497.
46. Dowdy SF, Hinds PW, Louie K, Reed SI, Arnold A, and Weinberg RA: Physical interaction of the retinoblastoma protein with human cyclins. Cell 1993;73:499-511.
47. kipl cyclin-dependent kinase inhibitor prevented by rapamycin. Nature (London) 1994;372:570-573.
48. Rusche JR, Javaherian K, McDanal C, Petro J, Lynn DL, Grimaila R, Langlois A, Gallo RC, Arthur LO, Fischinger PJ, Bolognesi DP, Putney SD, and Mattews TJ: Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120. Proc Natl Acad Sci USA 1988;85:3198-3202.
49. Takahashi H, Cohen J, Hosmalin A, Caese KB, Houghten R, Cornette JL, Delisi C, Moss B, Germain RN, and Berzofski JA: An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility complex molecule-restricted murine cytotoxic T lymphocytes. Proc Natl Acad Sci USA 1988;85:3105-3109.
50. Sattentau QJ and Moore JP: Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding. J Exp Med 1991;174:407-415.
51. Wyatt R, Moore J, Accola M, Desjardin E, Robinson J, and Sodroski J: Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding. J Virol 1995;69: 5723-5733.
52. Murakami T, Matushita S, Maeda Y, Takatuki K, Uchiyama T, and Hattori T: Applications of biotinylated V3 loop peptides of human immunodeficiency virus type 1 to flow cytometric analysis and affinity chromatographic techniques. Biochim Biophys Acta 1993;1181:155-162.
53. Xu Y, Murakami T, Kawase S, Uchiyama T, and Hattori T: Characterization of V3 loop-binding protein(s) of Molt-4 and U937 cells. AIDS Res Hum Retroviruses 1995;11:563-570.
54. Hattori T, Koito S, Takatuki K, Kido H, and Katunuma N: Involvement of tryptase-related cellular protease(s) in human immunodeficiency virus type 1 infection. FEBS Lett 1989;248:48-52.
55. Feng Y, Broder CC, Kennedy PE, and Berger EA: HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996;272:872-877.
56. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di-Marzio P, Marmon S, Sutton RE, Hill CM, Davis CB, Peiper SC, Schall TJ, Littman DR, and Landau NR: Identification of a major coreceptor for primary isolates of HIV-1. Nature (London) 1996; 381:661-666.
57. Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, Cayanan C, Maddon PJ, Koup RA, Moore JP, and Paxton WA: HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature (London) 1996;381:667-673.
58. Choe H, Farzan M, Sun Y, Sullivan N, Rollins B, Ponath PD, Wu L, Mackay CR, LaRosa G, Newman W, Gerard N, Gerard C, and Sodroski J: The β-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolate. Cell 1996;85: 1135-1148.
59. Graham GJ, Wright EG, Hewick R, Wolpe SD, Wilie NM, Donaldson D, Lorimore S, and Pragnell IB: Identification and characterization of an inhibitor of haematopoietic stem cell proliferation. Nature (London) 1990;344:442-444.
60. Broxmeyer HE, Sherry B, Lu L, Cooper S, Oh KO, Tekamp-Olson P, Kwon BS, and Cerami A: Enhancing and suppressing effects of recombinant murine macrophage inflammatory proteins on colony formation in vitro by bone marrow myeloid progenitor cells. Blood 1990;76:1110-1116.
61. Kolesnitchenko V, Wahl LM, Tian H, Sunila I, Tani Y, Hartman DP, Cossman J, Kaffeld M, Orenstein J, Samelson LE, and Cohen DI: Human immunodeficiency virus 1 envelope-initiated G2-phase programmed cell death. Proc Natl Acad Sci USA 1995;92: 11889-11893.